Literature DB >> 20363963

Hyperperfusion on magnetic resonance imaging in acute chemotherapy-related leukoencephalopathy.

Lisa Michael El-Hakam1, Melissa Beth Ramocki, James John Riviello, Anna Illner.   

Abstract

Acute chemotherapy-related leukoencephalopathy can present similar to acute stroke with symptoms including aphasia, dysarthria, and hemiplegia. Differentiation based on clinical appearance is challenging, and physicians must distinguish between the 2 conditions rapidly to institute appropriate therapies. An 8-year-old male with acute lymphoblastic leukemia receiving chemotherapy, including intrathecal methotrexate, presented to our emergency center with 2 hours of expressive aphasia and flaccid right hemiplegia. Emergent magnetic resonance imaging (MRI) was obtained, demonstrating diffusion restriction within bilateral corona radiata and centrum semiovale. Magnetic resonance perfusion revealed mildly increased perfusion, a finding inconsistent with ischemic stroke and previously unreported in acute chemotherapy-related leukoencephalopathy without necrosis. This increased perfusion conclusively eliminated stroke from the clinical differential. Magnetic resonance perfusion imaging proved valuable to rapidly distinguish acute chemotherapy-related leukoencephalopathy from ischemia, and the evaluation of perfusion alterations in this disorder may provide further insight into the pathophysiology of this entity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20363963      PMCID: PMC2936236          DOI: 10.1177/0883073809346349

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  14 in total

1.  Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy--a Pediatric Oncology Group study.

Authors:  D H Mahoney; J J Shuster; R Nitschke; S J Lauer; C P Steuber; N Winick; B Camitta
Journal:  J Clin Oncol       Date:  1998-05       Impact factor: 44.544

2.  MR perfusion, diffusion and BOLD imaging of methotrexate-exposed swine brain.

Authors:  Minna J Mäkiranta; Satu Lehtinen; Jukka P T Jauhiainen; Jarkko T Oikarinen; Juhani Pyhtinen; Osmo Tervonen
Journal:  J Magn Reson Imaging       Date:  2002-05       Impact factor: 4.813

3.  Disseminated necrotizing leukoencephalopathy following low-dose oral methotrexate.

Authors:  S Raghavendra; M D Nair; T Chemmanam; T Krishnamoorthy; V V Radhakrishnan; A Kuruvilla
Journal:  Eur J Neurol       Date:  2007-03       Impact factor: 6.089

4.  Metabolites of 5-fluorouracil, alpha-fluoro-beta-alanine and fluoroacetic acid, directly injure myelinated fibers in tissue culture.

Authors:  T Akiba; R Okeda; T Tajima
Journal:  Acta Neuropathol       Date:  1996-07       Impact factor: 17.088

5.  Magnetic resonance imaging in the evaluation of treatment-related central nervous system damage.

Authors:  R J Packer; R A Zimmerman; L T Bilaniuk
Journal:  Cancer       Date:  1986-08-01       Impact factor: 6.860

6.  Dextromethorphan is effective in the treatment of subacute methotrexate neurotoxicity.

Authors:  Richard A Drachtman; Peter D Cole; Carla B Golden; S Jill James; Stepan Melnyk; Jospeh Aisner; Barton A Kamen
Journal:  Pediatr Hematol Oncol       Date:  2002 Jul-Aug       Impact factor: 1.969

Review 7.  Stroke and cancer: a review.

Authors:  W Grisold; S Oberndorfer; W Struhal
Journal:  Acta Neurol Scand       Date:  2009-01       Impact factor: 3.209

8.  Clinical and radiological characteristics of methotrexate-induced acute encephalopathy in pediatric patients with cancer.

Authors:  H Inaba; R B Khan; F H Laningham; K R Crews; C-H Pui; N C Daw
Journal:  Ann Oncol       Date:  2007-10-17       Impact factor: 32.976

Review 9.  Stroke in patients with cancer: incidence and etiology.

Authors:  D M Cestari; D M Weine; K S Panageas; A Z Segal; L M DeAngelis
Journal:  Neurology       Date:  2004-06-08       Impact factor: 9.910

10.  Diffusion and perfusion imaging in subacute neurotoxicity following high-dose intravenous methotrexate.

Authors:  April F Eichler; Tracy T Batchelor; John W Henson
Journal:  Neuro Oncol       Date:  2007-05-23       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.